Immune checkpoint inhibitor-induced colitis: A comprehensive review

Aniruddh Som, Rohan Mandalaya, Dana Alsaadi, Maham Farshidpour, Aline Charabaty, Nidhi Malhotra, Mark C Mattar

Abstract

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target down-regulators of the anti-cancer immune response: Cytotoxic T-lymphocyte antigen-4, programmed cell death protein-1, and its ligand programmed death-ligand 1. ICIs have revolutionized the treatment of a variety of malignancies. However, many immune-related adverse events have also been described which mainly occurs as the immune system becomes less suppressed, affecting various organs including the gastrointestinal tract and causing diarrhea and colitis. The incidence of immune-mediated colitis (IMC) ranges from 1%-25% depending on the type of ICI and if used in combination. Endoscopically and histologically there is a significant overlap between IMC and inflammatory bowel disease, however more neutrophilic inflammation without chronic inflammation is usually present in IMC. Corticosteroids are recommended for grade 2 or more severe colitis while holding the immunotherapy. About one third to two thirds of patients are steroid refractory and benefit from infliximab. Recently vedolizumab has been found to be efficacious in steroid and infliximab refractory cases. While
in grade 4 colitis, the immunotherapy is permanently discontinued, the decision is controversial in grade 3 colitis.

**Key words:** Immune checkpoint inhibitors; Immune-related adverse events; Cytotoxic T-lymphocyte-associated antigen 4; Programmed cell death protein 1; Programmed death-ligand 1; Immune-mediated colitis

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Immune-mediated colitis (IMC) is a common immune related adverse event associated with immune checkpoint inhibitors. It typically occurs 5 wk-10 wk after the 2nd or 3rd dose of treatment. Endoscopically, it is indistinguishable from inflammatory bowel disease with significant overlap in histology. Optimal management of IMC requires early recognition and timely use of corticosteroids. About one third to two thirds of patients are steroid refractory. Infliximab is the second line therapy in these patients. Recent reports have shown that Vedolizumab is more gut specific and efficacious in steroid and infliximab refractory cases. Fecal microbiota transplant has recently been reported to be successful in steroid refractory cases.

**Citation:** Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, Mattar MC. Immune checkpoint inhibitor-induced colitis: A comprehensive review. *World J Clin Cases* 2019; 7(4): 405-418

**URL:** https://www.wjgnet.com/2307-8960/full/v7/i4/405.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v7.i4.405

**INTRODUCTION**

Scientists have long experimented with the idea that the immune system holds the potential to fight not only infections but also malignancy. In the early 19th century, Busch and Fehleisen, both noted that infecting tumors with erysipelas resulted in tumor regression[1,2]. Towards the late 1800s, sarcoma regression was seen after injecting tumors with heat-inactivated bacteria known as “Coley’s Toxins”[3]. The pivotal change in the history of immune checkpoint inhibitors (ICIs) began with the discovery of the T-cell receptor by Allison et al[4] in the early 1980s. This discovery was soon followed by the first ever reported human tumor antigen recognized by T-cells[5]. A study on tumors in animal models provided proof of concept that an antibody was successful in blocking the cytotoxic T-lymphocyte antigen 4 (CTLA-4)[6]. Such seminal work culminated with the Food and Drug Administration (FDA) approving the first ICI for use in metastatic melanoma in 2011[7]. To date there are 7 approved checkpoint inhibitors that target 3 main checkpoints, including cytotoxic T-lymphocyte associated protein 4 (CTLA-4; ipilimumab and tremelimumab), programmed cell death receptor 1 (PD-1; pembrolizumab and nivolumab), and programmed death ligand 1 (PD-L1; atezolizumab, avelumab, and durvalumab). Indeed, ICIs have become the standard of care for a number of cancers and resulted in the awarding of the 2018 Nobel Prize in Physiology or Medicine to Allison and Honjo in recognition of their contribution to the discovery of ICIs[8]. While representing a remarkable breakthrough in the treatment of several advanced malignancies, several ICI-related adverse events that affect multiple body systems (Table 1)[9-14]have been recognized, including immune-mediated colitis (IMC) and enteritis[9-16]. The incidence of IMC ranges from 0.3% to 7% and may be associated with other immune-related adverse events (irAEs)[17]. As a result, addressing GI irAEs has become a major clinical issue for physicians and patients alike. This review summarizes the current clinical information of IMC, its postulated mechanism of injury, endoscopic features, and the management strategies that are currently advocated.

**Mechanism of action**

The immune system has an important role in recognizing and eliminating tumors. Transformed tumor cells express tumor-associated antigens (TAAs) that are not seen on normal cells[17]. These TAAs are recognized by the immune system, and T cells can be stimulated in response to cellular presentation of TAAs[18]. TAAs are presented along with the major histocompatibility complex (MHC) I or II by specialized antigen-
Table 1 Percentage ranges of all grade immune-related common adverse events by checkpoint inhibitor class

| Class of immune checkpoint inhibitors | Approved agents | Rash | Diarrhea | Colitis | Elevated ALT | Hypothyroidism | Hypophysitis |
|--------------------------------------|-----------------|------|----------|---------|--------------|----------------|--------------|
| Anti CTLA-4                          | Ipilimumab, Tremelimumab | 12%-68% | 31%-49% | 7%-11.6% | 3%-9% | 4%-4.2% | 4%-6% |
| Anti PD-1                            | Nivolumab, Pembrolizumab | 11.7%-24% | 2.9%-11.5% | 1.3%-2.9% | 1.8%-7.1% | 3.4%-8.5% | 0.25% |
| Anti PD-L1                           | Atezolizumab, Durvalumab, Avelumab | 7.4% | 11.6%-23% | 0.7%-19.7% | 0.9%-4.0% | 5.0%-9.6% | 0.2% |

CTLA-4: Cytotoxic T-lymphocyte-associated antigen 4; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; ALT: Alanine aminotransferase.

Mechanisms of irAEs

Mechanisms of IMC and other irAEs are not fully understood; however, CTLA-4 blockade removes CTLA4-mediated protection from autoimmunity and is responsible for a large spectrum of autoimmune-side effects[30]. Immune-related toxicities are mostly associated with the inflammatory reaction produced by immune system responses against specific organs and tissues[29]. Immune-related T-cell activation leads to the secretion of high levels of CD4 T-helper cell cytokines and cytolytic CD8 T-cell tissue infiltration[31]. Another potential mechanism for generating colitis following anti-CTLA4 antibody involves CD25+CD4+ regulatory T cells (Treg). These immunosuppressive regulatory cells constitutively express high levels of CTLA-4 and data show increased autoimmune diseases in mice lacking Treg cells[32,33]. Consequently, it has been hypothesized that an antibody to CTLA4 might diminish Treg cells and induce autoimmunity[33].

The enterocolitis related to ipilimumab has features similar to graft-versus-host disease. It has been proposed that a contributing factor to enterocolitis in this setting may be intestinal microflora and bacterial antigens, representing an area of future research for prophylaxis of enterocolitis in patients treated with ipilimumab[32,34].

Clinical presentation

Diarrhea and enterocolitis lie along a clinical spectrum where diarrhea is defined as increased stool frequency, and enterocolitis is defined as abdominal pain, rectal
bleeding or the presence of mucus in stools with either clinical or radiologic objective evidence of entero-colonic inflammation, as defined by the American Society of Clinical Oncology (ASCO)\cite{13,36-38}. The presence of enterocolitis increases the risk of other complications, including ileus, colonic distension, and toxic megacolon, intestinal perforation, or even death. The clinical severity of both diarrhea and colitis is graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (Table 2). Mild diarrhea (grade 1) is defined as less than 4 stools per day above baseline. Grade 2 diarrhea is defined as 4 to 6 stools per day above baseline, while grade 2 colitis is characterized by abdominal pain or blood or mucus in the stool. Severe diarrhea (grade 3) is defined as ≥ 7 stools per day above baseline, and grade 3 colitis is defined by the presence of peritoneal signs with ileus and fever consistent with bowel perforation. A grade 4 designation is distinct from grade 3, reflecting increased severity and the life-threatening nature of symptoms.

While irAEs can affect any portion of the GI tract, the lower GI tract is most commonly involved. Less commonly, the upper GI tract can be affected, manifesting as aphthous ulcers, esophagitis, and gastritis. IMC and diarrhea typically occur 5 wk-10 wk after the 2nd or 3rd doses of treatment, but they have also been documented to occur as late as 4 mo after the last dose and may even recur one to two years after discontinuation of treatment\cite{13,38-40}.

**EPIDEMIOLOGY**

More than two-thirds of patients who receive anti-CTLA-4 therapy develop an irAE, and one-third of patients who are treated with anti-CTLA-4 therapy experience irAEs of the gastrointestinal tract, such as aphthous ulcers, esophagitis, gastritis, and enterocolitis, which usually presents as diarrhea\cite{19,49}. The incidence of diarrhea is higher in patients receiving anti-CTLA-4 agents, such as ipilimumab, compared to patients receiving anti-PD-1/PD-L1 agents, such as nivolumab or pembrolizumab\cite{46}, with grade 3/4 diarrhea seen in 10% vs 1%-2% of patients, respectively\cite{49}.

Beck et al\cite{47} showed that enterocolitis, defined by the presence of grade 3 or 4 symptoms and/or proven by biopsy, was the most common irAE associated with ipilimumab use, occurring in 21% of treated melanoma patients. Kwon et al\cite{48} reported a 5% incidence of grade 3/4 colitis among patients with prostate cancer who were treated with ipilimumab at the dose of 10 mg/kg. Slovin et al\cite{49} demonstrated that the incidence of grade 3/4 colitis increased from 13% to 16% with an increase in the dose of ipilimumab from 5 mg/kg to 10 mg/kg in patients with prostate cancer. Similarly, the incidence of enterocolitis in patients with renal cell carcinoma receiving higher doses of ipilimumab was 35% compared to 14% in patients receiving lower doses\cite{49}.

Overall, the risk of severe grade adverse events increased from 7% to 25% with an increase in the dose of ipilimumab from 3 mg/kg to 10 mg/kg\cite{49}. Most of the increase in adverse effects was due to an increase in the episodes of diarrhea. However, the toxicity profile would not increase if the dosage of nivolumab or pembrolizumab were increased from FDA approved doses (2 mg/kg every 3 wk) to higher doses (10 mg/kg every 2 wk or 3 wk). It may be argued that toxicities due to anti-CTLA-4 antibodies are dose-dependent whereas toxicities with anti-PD-1/anti-PD-L1 antibodies are perhaps independent of a dose-related effect\cite{49}.

**Combination therapy and risk of enterocolitis**

Combination therapies have so far only been approved for metastatic melanoma. Use of combined anti-CTLA4 and anti PD-1 agents results in increased frequency and severity of diarrhea and colitis than with the use of either agent alone\cite{47-49}. They can also cause rarer forms of toxicities like pancreatitis and small bowel enteritis which warrants discontinuation of ICI treatment and initiation of immnosuppressive therapy.

**Risk factors for ICI enterocolitis**

**Gut microbiome**: Baseline microbiota composition may predict ipilimumab-induced colitis. In one prospective study of 34 patients whose pre-treatment fecal composition was analyzed, an increased baseline presence of Bacteroidetes species was found in patients who remained free of colitis after ipilimumab treatment\cite{50}. Another study of 26 patients with metastatic melanoma treated with ipilimumab again showed that no-colitis related phylotypes were assigned to Bacteroidetes; most of the baseline colitis-associated phylotypes were related to Firmicutes\cite{50}. Compared with those whose baseline microbiota was driven by Bacteroides, patients with a baseline microbiota enriched with Faecalibacterium and Firmicutes had longer progression-free survival and overall survival.
Table 2. Grading the severity of immune checkpoint inhibitor-induced colitis and diarrhea based on Common Terminology Criteria for Adverse Events grade

| Grade  | Colitis                                      | Diarrhea                                      |
|--------|----------------------------------------------|-----------------------------------------------|
| 1      | Asymptomatic                                 | Increase of < 4 stools/d over baseline        |
| 2      | Abdominal pain, mucus, blood in stool        | Increase of 4-6 stools/d                      |
| 3      | Severe pain, fever, peritoneal signs         | Increase of ≥ 7 stools/d                      |
| 4      | Life-threatening consequences such as perforation, ischemia, necrosis, bleeding, toxic megacolon | Life-threatening consequences such as hemodynamic collapse |
| 5      | Death                                        | Death                                         |

Adapted from the Cancer Therapy Evaluation Program, National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 Program, Common Terminology Criteria for Adverse Events v5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.

Autoimmune disorders: Patients with a history of autoimmune disease, are at risk for worsening of their autoimmune disease while on immune checkpoint blockade, but immune-mediated toxicities are often mild and manageable without discontinuation of treatment\[^{51}\]. Patients that have experienced irAEs with prior checkpoint inhibitor therapy are at risk of developing irAEs following treatment with a different class of ICI; irAE risk also increases with dual therapy\[^{51,52}\].

Other risk factors: A recent series demonstrated that non-steroidal anti-inflammatory drug use was associated with an increased risk of ipilimumab-induced enterocolitis\[^{53}\]. Little data is available on the risk of immune-related colitis in patients with Crohn’s disease and ulcerative colitis.

**DIAGNOSIS**

Infectious causes of diarrhea should be ruled out with the first presentation of diarrhea or abdominal pain in patients treated with ICI therapy. Stool should be sent for standard microbiological examinations, including stool ova and parasites, bacterial culture, and *Clostridium difficile* testing\[^{40}\]. ICI-induced colitis and infection can coexist, as demonstrated by two case reports of co-infection by CMV and *Salmonella* species\[^{54,55}\]. Patients who are treated with antibiotics for infection may not experience complete resolution of symptoms, suggesting a concomitant ICI component to their colitis\[^{56}\].

While infections are more common, gastrointestinal metastases should also be ruled out as a potential etiology of symptoms. Patients with clinical signs of peritonitis such as fever, severe abdominal tenderness, distention, and rigidity should be evaluated with abdominal CT to rule out colonic perforation, which is a rare but well-documented adverse event that can be fatal\[^{57-59}\].

**Endoscopic features**

Colonoscopy, with an exam of the terminal ileum and biopsies of the colon and ileal mucosa, is the gold standard diagnostic test for ICI-mediated colitis in patients with persistent grade 2 or higher diarrhea. Patients with upper GI symptoms such as nausea or vomiting should also undergo EGD with biopsies. A normal appearance of the mucosa on endoscopic examination does not exclude enterocolitis, and mucosal biopsies must always be attained\[^{33}\].

Some patients with immune-mediated diarrhea or colitis may demonstrate ulcerations, but others may demonstrate erosions, erythema, loss of vascular pattern, or even grossly normal appearing mucosa (Figure 1)\[^{60}\]. Ipilimumab-induced colitis most often involves lesions of the rectum and sigmoid, so flexible sigmoidoscopy is usually sufficient for diagnosis. A majority of patients, however, also have endoscopic lesions proximal to the sigmoid. In more extensive colitis, inflammation can be either patchy or continuous\[^{53,61}\]. Studies have shown no correlation between diarrheal grade or severity of abdominal pain and endoscopic appearance, but bloody stools have been correlated with higher endoscopic Mayo scores\[^{95,96}\].

**Histology**

ICI colitis presents with an array of histologic findings ranging from focal active colitis with patchy crypt abscesses to diffuse mucosal inflammation\[^{10,11}\]. Biopsies most commonly demonstrate features of acute colitis such as increased cellularity of the
Patient who experienced immune-mediated colitis 4 wk after ipilimumab therapy. Colonoscopy showed a sigmoid colon with ulcers, diffuse erythema, and loss of vascularity.

Histologic findings may precede the onset of diarrhea or colitis. One study of asymptomatic patients who underwent colonoscopy 1 wk-2 wk following ipilimumab induction demonstrated that inflammatory changes were already present prior to symptoms (which occurred 3 wk later in the majority of patients). Biopsies most frequently showed focal neutrophilic cryptitis and neutrophilic infiltration in the lamina propria, and a subset of patients had excess plasma cells in the lamina propria and lymphocytic cryptitis. When a subset of these patients did eventually present with symptomatic diarrhea or colitis within 24 wk of induction, their biopsies showed more severe infiltration of the lamina propria with mixed inflammatory cells (neutrophils, lymphocytes, plasma cells, and eosinophils), neutrophilic cryptitis and crypt abscesses, as well as glandular destruction and mucosal erosions or ulcers. This study did not show a significant increase in the number of intraepithelial lymphocytes, apoptotic activity, or histologic evidence of chronicity, such as crypt architectural distortion, basal plasmacytosis, the presence of granulomas, Paneth cell metaplasia, or pyloric metaplasia. As several other studies have also shown a relative lack of chronic inflammation on histology, the pathogenesis of ICI-induced enterocolitis is generally considered distinct from that of IBD, although both diseases have similar clinical presentations.

However, the finding of chronic inflammation changes in some ICI-treated patients has caused speculation that their presence is consistent with the progression of acute inflammation or the development of IBD. More recent studies have shown that some patients do exhibit intraepithelial lymphocytes or basal lymphocytes and crypt architecture distortion, which is more consistent with findings in chronic colitis. One study found features of chronic colitis in three out of nine patients with endoscopic or histological inflammation on biopsies that were taken several months after the onset of enterocolitis.

Interestingly, one recent study demonstrated distinct immunological characteristics of colonic biopsies taken from patients with IMC and IBD that were analyzed by immunohistochemistry and flow cytometry. The lamina propria and epithelium of anti-PD-1-induced colitis was predominantly characterized by CD8⁺ T-cells, whereas the lamina propria in anti-CTLA-4-induced colitis was predominantly characterized by CD4⁺ T-cells and high mucosal TNFα concentrations. In IBD or anti-PD-1-induced colitis, Treg cells were predominant, whereas in anti-CTLA-4-induced colitis more conventional CD4⁺ cells were found.

Similarities between IMC and IBD still persist though these differences are helpful. As histologic features may overlap, clinical factors must be utilized to differentiate these distinct clinical entities, including disease onset soon after initiation of ICI or other associated symptoms. IMC is one of the most common irAEs, but patients often exhibit other concomitant irAEs such as hepatitis, hypophysitis, and hypothyroidism; if any of these also coincide in a patient with diarrhea, ICI colitis is much more likely than IBD.

**Stool or serologic markers of ICI colitis**

Identification of serologic markers specific to IMC has been an important focus of research. Fecal calprotectin is a marker that has high sensitivity and specificity for intestinal inflammation. Calprotectin is a calcium-binding protein derived primarily from neutrophils and activated macrophages. While calprotectin can be used to
distinguish inflammatory from noninflammatory diarrhea, it is not specific for ICI-induced colitis[60]. Further, while fecal calprotectin can be elevated in patients receiving ipilimumab, indicating active bowel inflammation, it does not predict the onset of colitis. There are few reports regarding the use of new novel markers to diagnose IMC. In one report by Callahan et al[60] patients with melanoma treated with ipilimumab who developed colitis had higher on-treatment serum concentrations of interleukin 17 compared with those without colitis. Another study reported that an increase in the number of eosinophils from baseline after treatment was associated with the advent of irAEs[61]. Whether these are predictors of who will develop colitis on treatment or just markers of active inflammation is still unclear. Plasma CRP and albumin may be helpful but again can be affected by other systemic inflammatory processes[62]. ICI-induced enterocolitis is one of the most commonly occurring irAEs, but the differential diagnosis for diarrhea in ICI-treated patients should also include other irAEs that manifest as diarrhea, such as ICI-induced hyperthyroidism or celiac disease.

**MANAGEMENT**

Optimal management of immune-mediated enterocolitis requires early recognition and timely use of immunosuppressive agents which are chosen based on the severity of the colitis as determined by the CTCAE[63]. For mild grade 1 diarrhea, defined as less than 4 stools per day above baseline, patients may continue ICI therapy with symptomatic treatment of diarrhea with loperamide and electrolyte repletion[56]. For grade 2 diarrhea or colitis, defined as 4 to 6 stools per day above baseline, abdominal pain, or blood or mucus in the stool, infectious causes must be ruled out prior to initiation of immunosuppressive agents. Checkpoint inhibitor therapy should be withheld, and oral corticosteroids initiated at 0.5-1 mg/kg per day if symptoms persist for > 1 wk and tapered over 1 mo-2 mo[70].

For severe grade 3 or 4 toxicity, defined as ≥ 7 stools above baseline per day or the presence of peritoneal signs with an ileus and fever consistent with bowel perforation, checkpoint inhibitor therapy should be permanently discontinued. Patients with grade 3 or 4 toxicity are usually hospitalized for intravenous fluid resuscitation and expedited initial workup and treatment. Systemic corticosteroids are initiated at 1-2 mg/kg per day (prednisone or equivalent) once bowel perforation is excluded and *Clostridium difficile* infection is ruled out.

Overall, one-third to two-thirds of patients either do not respond to high-dose intravenous steroids, or have a relapse requiring an increase in the corticosteroid dosage during the course of steroid tapering[56]. In a recent study of 92 patients who developed diarrhea/colitis on immunotherapy for melanoma or lung cancer, in 54 (56%) episodes, patients had corticosteroid-refractory colitis[56]. Recent studies suggest that the presence of colonic ulcers on endoscopic exam of patients with ipilimumab-induced colitis predict a steroid refractory course[56,61,62]. One study of 92 patients with ICI-colitis requiring corticosteroid therapy found that ulcers, pancolitis, and high Mayo scores or high van der Heide scores, which assess the severity of colitis based on endoscopic features, predict the likelihood that patients may be steroid-refractory and need infliximab[65,67,68]. Patients that require infliximab usually have an excellent response. If there is no improvement in symptoms within 3 d to 5 d of high-dose steroids, then immunosuppressive therapy with the anti-TNFα inhibitor infliximab is started at 5 mg/kg dosed every 2 wk until resolution of symptoms[56]. There are few differences in the management guidelines established by the Society for Immunotherapy of Cancer (SITC), ASCO, and European Society of Medical Oncology (ESMO) (Table 3)[55,56,79].

All of the clinical guidelines recommend permanently discontinuing ICIs for grade IV colitis. For grade III colitis, recommendations vary. SITC recommends resuming ICI once corticosteroid is tapered to ≤ 10 mg/d and the patient remains symptom-free. ASCO recommends considering permanent discontinuation of CTLA-4 agents, while PD-1 or PD-L1 agents may be restarted if the patient can recover to grade 1 or less. ESMO does not make any clear recommendations regarding resuming ICI in grade 3 diarrhea/colitis. All of the societies agree that resuming ICI may be considered in grade II diarrhea once improvement is noted.

While infliximab has been successfully used to achieve clinical resolution in many patients with ICI-induced colitis, its use may be limited in those who are refractory or those who have contraindications to anti-TNFα therapy, including patients with a history of latent tuberculosis or chronic carriers of hepatitis B virus[69-71]. Historically infliximab use has notably been associated with skin cancers and with lymphomas (Hodgkin’s, non-Hodgkin’s, and hepatosplenic T-cell) in younger populations, but
Table 3  Management of immune checkpoint inhibitor-induced colitis and diarrhea based on Common Terminology Criteria for Adverse Events grade, as summarized by the Society for Immunotherapy of Cancer, American Society of Clinical Oncology, and European Society of Medical Oncology

| Grade of colitis | Society for Immunotherapy of Cancer recommendations | American Society of Clinical Oncology recommendations | European Society for Medical Oncology recommendations |
|------------------|----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Grade 1          | Continue ICI; Close follow up within 24 h-48 h; If symptoms persist, routine stool and blood tests; Bland diet during period of acute diarrhea; Anti-diarrheal medication is optional but not highly recommended but only if infectious work-up is negative | May continue ICI or hold ICI temporarily and resume if toxicity does not exceed grade 1. Monitor for dehydration and recommend dietary changes; Expedited phone contact with patient/caregiver; May obtain gastroenterology consult for prolonged grade 1 cases | continue ICI; if symptomatic, treat with oral fluids, loperamide, avoid high fiber and lactose in diet; if persists > 14 d treat with prednisolone 0.5 mg/kg-1 mg/kg or oral budesonide 9 mg daily; Blood tests: FBC, UEC, LFTs, CRP, TFFs; Stool microscopy for ova and parasites, culture, viral PCR, C difficile toxin and cryptosporidia |
| Grade 2          | Hold ICI; Outpatient stool and blood work; CRP, ESR, fecal calprotectin, lactoferrin, imaging and endoscopy are optional; If diarrhea only, observe for 2 d-3 d. If no improvement start prednisone 1 mg/kg per day (or equivalent dose of methylprednisolone); anti-diarrheal medication is not recommended; If diarrhea and colitis symptoms (abdominal pain ± blood in BM), start prednisone 1 mg/kg per day (or equivalent dose of methylprednisolone) immediately; If no improvement in 48 h, increase corticosteroid dose to prednisone 2 mg/kg per day (or equivalent dose of methylprednisolone); If patient improves, taper corticosteroid over 4 wk-6 wk; Resume ICI when corticosteroid is tapered to ≤ 10 mg/d and patient remains symptom-free (grade ≤ 1); Continue anti-PD-1 or anti-PD-L1 monotherapy; If using combination anti-CTLA-4/anti-PD-1 immunotherapy, continue anti-PD-1 agent only; ICI dose reduction is not recommended; If colitis returns on resuming ICI: Grade ≤ 2: Temporarily stop ICI | Hold ICI until symptoms recover to grade 1 or less; Consider permanently discontinuing CTLA-4 agents; may restart PD-1, PD-L1 agents if recovers to grade 1 or less. Concurrent immunosuppressant maintenance therapy (< 10 mg prednisone equivalent dose) if clinically indicated in individual cases; Supportive care with loperamide if infection ruled out; Consult gastroenterology; Administer corticosteroids starting with an initial dose of 1 mg/kg per day prednisone or equivalent; When symptoms improve to grade 1 or less, taper corticosteroids over at least 4 wk to 6 wk before resuming treatment, although resuming treatment while on low-dose corticosteroid may also be an option after an evaluation of the risks and benefits; Endoscopic evaluation to stratify patients for early treatment with infliximab based on the endoscopic findings and to determine the safety of resuming PD-1, PD-L1 therapy; Testing for stool inflammatory markers, lactoferrin, or calprotectin to differentiate functional versus inflammatory diarrhea. Calprotectin testing may also be offered to monitor treatment response; Repeat colonoscopy is optional and may be offered for cases of grade 2 or higher for disease activity monitoring to achieve complete remission, especially if there is a plan to resume ICI | Hold ICI; Symptomatic management as above; If persists > 3 d or worsens, treat with Prednisolone 0.5 mg/kg-1 mg/kg or oral budesonide 9 mg daily; Schedule colonoscopy but do not wait for colonoscopy to start therapy; Baseline testing as above; consider abdominal X-ray for signs of colitis; Contact patient every 72 h; If no improvement in 72 h or worsening or absorption concern, treat as grade 3 with IV steroid |
Grade 3

| Event                                                                 | Management                                                                 |
|----------------------------------------------------------------------|----------------------------------------------------------------------------|
| Grade 3: withhold ICI; consider resuming ICI when corticosteroid is    | Should consider permanently discontinuing CTLA-4 agents and may restart PD-1, PD-L1 agents if patient can recover to grade 1 or less; Should administer corticosteroid (initial dose of 1 mg/kg to 2 mg/kg per day prednisone or equivalent); Should refer to hospitalization or outpatient facility for patients with dehydration or electrolyte imbalance; If symptoms persist ≥ 3 d to 5 d or recur after improvement, may administer IV corticosteroid or noncorticosteroid (e.g., infliximab); May offer coloscopy in cases where patients have been on immuno suppression and may be at risk for opportunistic infections as an independent cause for diarrhea (i.e., CMV colitis) and for those who are anti-TNF or corticosteroid refractory. |
| tapered to ≤ 10 mg/d and patient remains symptom-free (grade ≤ 1).    | Permanently discontinue all ICI treatment; Should admit patient when clinically indicated. Patients managed as outpatients should be very closely monitored; Should administer IV corticosteroid until symptoms improve to grade 1 and then start taper over 4 wk to 6 wk; May offer early infliximab 5 mg/kg to 10 mg/kg if symptoms are refractory to corticosteroid within 2 d to 3 d; May offer lower Cl endoscopy if clinically indicated. |
| Consider hospitalization; Grade 4:                                     |----------------------------------------------------------------------------|
| Permanently discontinue ICI and hospitalize; Blood and stool infection | No distinction from Grade 3; Taper steroids over 2 wk-4 wk if moderate symptoms and 4 wk-8 wk if severe |
| work-up, inflammatory markers, imaging, endoscopy and GI consult;    |----------------------------------------------------------------------------|
| Start intravenous prednisone 1-2 mg/kg per day (or equivalent dose of  |
| methylprednisolone) immediately; If patient improves, follow instructions|----------------------------------------------------------------------------|
| for “If patient improves” for grade 2; If refractory or no improvement on  |
| IV corticosteroid, start prednisone 2 mg/kg per day (or equivalent dose of  |
| methylprednisolone) for 3 d; Consider other anti-inflammatory agents e.g., infliximab 5 mg/kg, which can be given again after two weeks if a second dose is needed. Vedolizumab may also be used |

Grade 4

| Event                                                                 | Management                                                                 |
|----------------------------------------------------------------------|----------------------------------------------------------------------------|
| Should permanently discontinue all ICI treatment; Rest same as grade 3| Permanently discontinue all ICI treatment; Should admit patient when clinically indicated. Patients managed as outpatients should be very closely monitored; Should administer IV corticosteroid until symptoms improve to grade 1 and then start taper over 4 wk to 6 wk; May offer early infliximab 5 mg/kg to 10 mg/kg if symptoms are refractory to corticosteroid within 2 d to 3 d; May offer lower Cl endoscopy if clinically indicated. |

ICI: Immune checkpoint inhibitors; FBC: Full blood count; UEC: Urea, electrolytes, creatinine; LFTs: Liver function tests; CRP: C-reactive protein; TFTs: Thyroid function tests; PCR: Polymerase chain reaction; CTLA-4: Cytotoxic T-lymphocyte-associated antigen 4; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; NYHA: New York Heart Association; CHF: Congestive heart failure.

more recent studies suggest that these associations are confounded by prior thiopurine use and by overall increased risk of malignancies in the IBD population whose use of infliximab is the most studied[83,84]. One recent meta-analysis of 11702 patients with cancer history who were followed for 31258 person-years found that there was no increased risk of cancer recurrence in those exposed to anti-TNFα agents[85]. For patients who do not respond to the first or second dose of infliximab, drug trough levels should be obtained to determine whether dose escalation would be beneficial such as in those who have low trough levels[86]. Patients with adequate drug levels are likely primary non-responders and need to switch to a different drug class.

Treatment algorithms do not currently suggest the use of any immunosuppressants other than anti-TNFα agents in the treatment of irAEs such as colitis. There are few published reports in the literature demonstrating the use of vedolizumab in the treatment of ICI-induced colitis[87,88]. Vedolizumab, an antibody against the α4β7-integrin on the surface of CD4+ T cells, is approved for the treatment of inflammatory bowel diseases. Bergqvist et al[89] reported on 7 cases of steroid-dependent or steroid-refractory ICI-induced colitis successfully treated with vedolizumab, which has a uniquely gut-specific mechanism of action in that it prevents T cells from binding and homing into the inflamed bowel mucosa, which can explain its efficacy in ICI-mediated enterocolitis. Vedolizumab was administered with infusions of 300 mg at time-points 0 wk, 2 wk, and 6 wk or until clinical and laboratory regression was observed[90]. Vedolizumab’s gut selectivity potentially allows minimization of the potential risk for cancer progression in patients known to have metastasis involving lymph nodes[91]. Vedolizumab use is thought to mitigate the antitumor effect of ICIs to a lesser extent potentially and to have the additional benefit of not heightening the risk of secondary malignancies in an already vulnerable patient as is a potential with infliximab use. Further studies are needed to establish the role of vedolizumab in the therapeutic algorithm for ICI-induced enterocolitis.

For patients that develop a colonic perforation, with or without intra-abdominal abscess, either initially or during the course of medical treatment, emergency colectomy is indicated. A subtotal colectomy may be recommended because colonic lesions are generally extensive and segmental colonic resection is generally followed
by severe inflammation of the remaining colon in the postoperative phase\[53\].

**Colitis relapse risk associated with ICI resumption**

In one recent study, four out of six patients who had an additional infusion of ipilimumab after going into enterocolitis remission relapsed\[53\]. Among them, three patients required a new steroid course, including one patient who had a severe steroid-refractory relapse requiring infliximab infusion. Reintroduction of anti-CTLA4 in patients, who had previously experienced enterocolitis, poses a high risk of relapse and should be discussed on an individual basis.

**Prevention**

To date, there have been no studies that demonstrate effective measures to prevent ICI-induced colitis. One randomized, double-blind, placebo-controlled study of 115 patients receiving ipilimumab investigated the efficacy of concomitant budesonide as prophylaxis against colitis. The authors found that prophylactic steroids did not show a benefit in the tolerability of ipilimumab and did not alter the frequency of grade ≥ 2 diarrhea compared to placebo\[65,84\].

While rare, bowel perforation is an irAE with fatal consequences. Smith et al\[85\] noted that in a cohort of 22 patients treated with ipilimumab followed by high-dose IL-2 therapy, 3 patients experienced perforation and subsequently required emergency laparotomy. This was found to be more significant compared to 8 perforations among 1797 patients treated with IL-2 alone and compared to 4 perforations among 198 patients treated with ipilimumab alone\[84\]. To reduce the risk of this complication, the authors recommended that patients who have received prior anti-CTLA4 therapy, and who plan to receive treatment with IL-2, undergo diagnostic colonoscopy before initiating IL-2 to rule out chronic active colitis even in the absence of symptoms\[85\].

**Prognosis of cancer in patients with IMC**

Current theories suggest that increased irAEs predict improved response to checkpoint inhibitors and improved overall survival\[62\]. One study of 117 patients treated with ICIs who experienced diarrhea found that diarrhea is an independent predictor of improved survival regardless of treatment requirement, and that immunosuppressive treatment for diarrhea did not significantly affect overall survival\[13\].

**CONCLUSION**

IMC is one of the most common adverse effects associated with checkpoint inhibitors. Those who experience persistent grade 2 or above diarrhea or abdominal pain should undergo infectious work up and colonoscopy with biopsies. Endoscopic features of IMC range from normal appearing mucosa to erosions, erythema, and loss of vascular pattern, to ulcerations. Symptom severity does not correspond with endoscopic appearance. While IMC shares some clinical characteristics with inflammatory bowel disease. IMC biopsies typically demonstrate findings of acute colitis such as increased cellularity of the lamina propria, intraepithelial neutrophilic infiltrates, and crypt abscesses rather than characteristics of chronic colitis such as intraepithelial or basal lymphocytes and crypt architecture distortion. Most patients with IMC respond to corticosteroids. Patients refractory to steroids are treated with short-term biologic therapy including infliximab or the gut-specific vedolizumab. Immunotherapy may be resumed in patients with IMC who respond to treatment except for those with grade 4 colitis. Multidisciplinary collaboration among gastroenterologists, oncologists and pathologists is necessary to better characterize this immune-mediated adverse event and improve upon current standard management algorithms.

**REFERENCES**

1. Busch W. Aus der Sitzung der medicinischen Section vom 13 November 1867. Berlin Klin Wochenschr 1868; 5:137.
2. Fehleisen F. Über die Züchtung der Erysipelkokken auf künstlichem Nährboden und ihre übertragbarkeit auf den Menschen. Dtsch Med Wochenschr 1882; 8: 553-554 [DOI: 10.1055/s-0029-1196806]
3. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006; 26: 154-158 [PMID: 16789460]
4. Allison JP, McIntyre BW, Bloch D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol 1982; 129: 2293-2300 [PMID: 6181166]
5. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science
Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients
Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL,
49-57 [PMID: 23849743 DOI: 10.1016/j.jaut.2013.06.006]
Hansen JBAG, Carbonell F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines
Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol 2017; 28: i119-i142 [PMID: 28881921 DOI:
10.1093/annonc/mdx225]
Nagai H, Muto M. Optimal management of immune-related adverse events resulting from treatment with
immune checkpoint inhibitors: a review and update. J Int Clin Oncol 2018; 23: 410-420 [PMID: 29562162
DOI: 10.1007/s10147-018-1299-6]
González-Rodríguez E, Rodríguez-Abru D; Spanish Group for Cancer Immuno-Biotherapy (GETICA).
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist 2016;
21: 804-816 [PMID: 2730691 DOI: 10.1634/theoncologist.2015-0509]
Wang Y, Abu-Sheth H, Mao E, Ali N, Ali FS, Qiao W, Lum P, Raju G, Shuttleworth G, Stroehlein J,
Diab A. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies:
retrospective review at MD Anderson. J Immunother Cancer 2018; 6: 37 [PMID: 29747688 DOI:
10.1186/s40425-018-0346-6]
Moore C, Chen I. Immunotherapy in Cancer Treatment: A Review of Checkpoint Inhibitors. US Pharm
2018; 43: 27-31
Sharpe AH. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol Rev 2017; 276: 5-
8 [PMID: 28258698 DOI: 10.1111/imr.12351]
Chasca DM, Rakela J. Knowns and Unknowns: The Safety and Efficacy of Cancer Immunotherapy in
Chronic Liver Disease. Curr Hepatology Rep 2018; 17: 153-155 [DOI: 10.1007/s10147-018-0048-5]
Frieu-Klotz C; Dior M, Dunette D, Demenic J, Brezaal M, Bremazali V, Chaussade S, Conat R. Immune
Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. Target Oncell 2017; 12: 301-
308 [PMID: 28540478 DOI: 10.1159/00047-01495-4]
Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalbera P, Mortarini R, Arancia G, Anichini
A, Fais S, Parmigiani G. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.
Immunol Rev 2002; 188: 97-113 [PMID: 12445284 DOI: 10.1034/j.1600-6065.2002.18809.x]
Melo E, Hervas-Stubbis S, Gleimie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies
for cancer therapy. Nat Rev Cancer 2007; 7: 95-106 [PMID: 17251916 DOI: 10.1038/nrc2051]
Nagorsen D, Scheibenberg C, Marincola FM, Letsch A, Kelhoul Z. Natural T cell immunity against cancer.
Clns Cancer Res 2003; 9: 4296-4303 [PMID: 15455498 DOI: 10.1371/journal.pone.012824]
Tarhini A. Immune-mediated adverse events associated with ipilimumab cta-4 blockade therapy: the
underlying mechanisms and clinical management. Scientifica (Cairo) 2013; 2013: 857519 [PMID:
24278787 DOI: 10.1155/2013/857519]
Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a
CD28-IT-dependent mechanism. J Immunol 2006; 177: 1052-1061 [PMID: 16818761 DOI: 10.4049/jim-
munol.177.2.1052]
Wang W, Lan R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma
antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. J Immunol 2009; 201: 1065-1077
[PMID: 19651641 DOI: 10.4049/jimmunol.297]
Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer
Immunol Immunother 2009; 58: 823-830 [PMID: 19199837 DOI: 10.1007/s00262-008-0653-8]
Robert C, Ghiringhelli F. What is the role of cytokine T lymphocyte-associated antigen 4 blockade in patients
with metastatic melanoma? Oncologist 2009; 14: 848-861 [PMID: 19648604 DOI: 10.1634/the-
colegist.2009-0028]
Kaehler KC. Piel S, Livingstone F, Schilling B, Hauschild A, Schadendorf D. Update on immunologic
therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response
patterns, immune-related adverse events, and their management. Semin Oncol 2010; 37: 485-498 [PMID:
20174604 DOI: 10.1056/simoncol.2010.09.003]
Ohle DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, Mihm M, Hasserrjan R,
Laubers GY. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical
analysis. Am J Surg Pathol 2008; 32: 1130-1137 [PMID: 18545145 DOI:
10.1097/PAS010031817150c3]
Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S.
Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther
2014; 7: 203-209 [PMID: 24570590 DOI: 10.2147/OTT.S57355]
Bourke JM, O’Sullivan M, Khattak MA. Management of adverse events related to new cancer
immunotherapy (immune checkpoint inhibitors). Med J Aust 2016; 205: 418-424 [PMID: 27897399
DOI: 10.5694/jm.2016.00586]
Brookow ME, Jeffery EW, Hjerrild KA, Paepker B, Clark LB, Yasayko SA, Wilkinson JE, Galas D,
Ziegler SF, Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal
lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27: 68-73 [PMID: 11138001 DOI:
10.1093/complex.10.0.3784]
Read S, Malmström V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in
the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;
192: 295-302 [PMID: 1089916 DOI: 10.1084/jem.192.2.295]
Walker LS. Treg and CTLA-4: two interwining pathways to immune tolerance. J Autoimmun 2013;
45: 49-57 [PMID: 23849743 DOI: 10.1016/j.jauto.2013.06.006]
Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammla US, Topalian SL,
Sherry RM, Kleiner D, Quazaudo M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients
with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. *J Clin Oncol* 2006; 24: 2283-2289. [PMID: 16710025 DOI: 10.1200/JCO.2005.04.5716]

34 Gutthery SL, Heube JF, Filipovich A. Enteral metronidazole for the prevention of graft versus host disease in pediatric marrow transplant recipients: results of a multi-center study. *Bone Marrow Transplant* 2004; 33: 1235-1239. [PMID: 15077127 DOI: 10.1038/sj.bmt.1704474]

35 Postow MA. Managing immune checkpoint-blocking antibody side effects. *Am Soc Clin Oncol Educ Book* 2015; 35: 76-83. [PMID: 22993145 DOI: 10.14389/edbk.am.2015.35.57.6]

36 Puzza L, Dia B, Abdallah K, Bingham CO, Brougn C, Dadu R, Harmad L, Kim S. Lacouture ME, LeBoeuf NB, Lenihan D, Onofrei C, Shannon V, Sharma R, Srik AM, Wine D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. *J Immunother Cancer* 2017; 5: 975. [PMID: 29166004 DOI: 10.1186/s40428-017-0271-x]

37 Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. *Front Pharmacol* 2017; 8: 49 [DOI: 10.3389/fphar.2017.00049]

38 Abu-Shieh H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, Richards DM, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. *J Immunother Cancer* 2018; 6: 142. [PMID: 30518410 DOI: 10.1186/s40428-018-0461-4]

39 Graziani G, Tenori L, Navarra P. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. *Pharmacol Rev* 2012; 65: 9-22. [PMID: 21930211 DOI: 10.1177/0031861911013175]

40 Gupta A, De Felice K, Lofus EV, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. *Aliment Pharmacol Ther* 2015; 42: 406-417. [PMID: 26002850 DOI: 10.1111/apt.13281]

41 Hofmann L, Farchoner A, Loqui C, Goldinger SM, Zimmer L, Ugueral S, Schmidt MI, Gutzner R, Utikal JS, Goppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berkling C, Gesierich A, Krakhardt AM, Schaden D, Schuler G, Dummer R, Heinzerling LM. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effect of anti-PD-1 therapy. *Eur J Cancer* 2016; 60: 190-209. [PMID: 27085602 DOI: 10.1016/j.ejca.2016.02.025]

42 Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Toxicities of the anti-PD-1 and anti-CTLA-4 immune checkpoint co-blocking antibodies. *Am J Clin Oncol* 2016; 27: 1362. [PMID: 27672927 DOI: 10.1093/ajco/mdi141]

43 Kwon ED, Drake CG, Scher H, Fizazi K, Bossi A, van den Eertwegh AJ, Kainer M, Houeide N, Santos R, Mahamedmi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleacu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol* 2014; 15: 700-712. [PMID: 24831977 DOI: 10.1016/S1470-2045(14)70189-5]

44 Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher H, Chin K, Gagnier P, McHenry MB, Beer TM. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. *Ann Oncol* 2013; 24: 1813-1821. [PMID: 23535954 DOI: 10.1093/annonc/mdt107]

45 Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. *Front Pharmacol* 2017; 8: 49 [DOI: 10.3389/fphar.2017.00031]

46 Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Delaforcade D, Dunner R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haenen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Szolm Z, Dreno B, Bachtold L, Young A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* 2015; 373: 23-34. [PMID: 26027431 DOI: 10.1056/NEJMoa1404030]

47 Hodi FS, Chnei JV, Pavlick AC, Robert C, Gonsford BM, McDermott DF, Linette G, Meyer N, Giguere JK, Agarwala SS, Shaeheen A, Ernststoff MS, Minor DR, Sandhu AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined Nivolumab and Ipilimumab versus Ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled phase 2 trial. *Lancet Oncol* 2016; 17: 1558-1568. [PMID: 27620977 DOI: 10.1016/S1470-2045(16)30366-7]

48 Postow MA, Chnei JV, Pavlick AC, Robert C, Grossmann K, McDermott DF, Linette G, Meyer N, Giguere JK, Agarwala SS, Shaeheen A, Ernststoff MS, Minor DR, Sandhu AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled phase 2 trial. *Lancet Oncol* 2016; 17: 1558-1568. [PMID: 27620977 DOI: 10.1016/S1470-2045(16)30366-7]

49 Bowyer S, Prithavisir P, Lorigan P, Larkin J, McArthur G, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Bone Marrow Transplant in Pediatric Marrow Transplant Recipients: Results of a Pilot Study. *Bone Marrow Transplant* 2004; 33: 2283-2289. [PMID: 16710025 DOI: 10.1200/JCO.2005.04.5716]

50 Meneses AM, Johnson OH, Ramankumar S, Atkinson VG, Wang AN, Park JJ, Di Scalzi A, Tsai SK, Erolgu Z, Klein O, Hassel JC, Somasa JA, Gurnske A, Sullivan RJ, Bards S, Alvaro MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. *Ann Oncol* 2017; 28: 368-376. [PMID: 28876304 DOI: 10.1093/annonc/mdx343]

51 Bowyer S, Prithavisir P, Lorigan P, Larkin J, McArthur G, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Bone Marrow Transplant in Pediatric Marrow Transplant Recipients: Results of a Pilot Study. *Bone Marrow Transplant* 2004; 33: 2283-2289. [PMID: 16710025 DOI: 10.1200/JCO.2005.04.5716]

52 Marthoy L, Mateca C, Musta C, Nachbury M, Nance S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier
Immune checkpoint inhibitor-induced colitis

JF, Bourdier de Beauregard M, Mortier L, Coutuz C, Soulauer E, Lanoy E, Kapel N, Planchar D, Chaput N, Robert C, Carbonnel F. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis 2016; 10: 395-401 [PMID: 26733345 DOI: 10.1038/eco-jcc/jjv227]

McCutcheon JL, McClain CM, Puzanov I, Smith TA. Infectious Colitis Associated With Iplimumab Therapy. Gastroenterology 2014; 7: 28-31 [PMID: 27785266 DOI: 10.1016/j.gie.2014.05.034]

Lankes K, Hundofoan G, Harrer T, Pomeraj AE, Agaimy A, Angelovska I, Tajmir-Riahi A, Göhl J, Schuerle G, Neurath MF, Hohenberger W, Heinecker L. Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis. Oncoimmunology 2016; 5: e1128611 [PMID: 27471608 DOI: 10.2147/oncojl.2015.112661]

Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjørnsson P, van Thielen JV, van Leerdam ME, van den Heuvel M, Blank CU, van Dieren J, Haanen JAG. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 2018; 3: e000278 [PMID: 29738470 DOI: 10.1136/esmoopen-2017-000278]

Dilling P, Waleczak J, Piskul P, Kruszewski WJ. Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with iplimumab - case report. Pol Przegl Chir 2014; 86: 94-96 [PMID: 24670341 DOI: 10.2478/pjp-2014-0017]

Burdine L, Lai K, Laryea JA. Iplimumab-induced colonic perforation. J Surg Case Rep 2014; pii: rju010 [PMID: 24876393 DOI: 10.1038/jrcc/rju010]

Shah R, Witt D, Asif T, Mir FF. Iplimumab as a Cause of Severe Pan-Colitis and Colonic Perforation. Cureus 2017; 9: e1182 [PMID: 28533998 DOI: 10.7759/cureus.1182]

Verschuren EC, van den Eertwegh AJ, Wonders J, Stangen RM, van Delft F, van Bodegraven A, Neefjes-Borst A, de Boer NK, Clinic Endoscopic, and Histologic Characteristicts of Iplimumab-Associated Colitis. Clin Gastroenterol Hepatol 2014; 12: 836-842 [PMID: 26748223 DOI: 10.1016/j.cgh.2015.12.028]

Jain A, Lipson EJ, Sharifiant WH, Brant SR, Lazarev MG. Colonic ulcerations may predict steroid-refractory course in patients with iplimumab-mediated enterocolitis. World J Gastroenterol 2017; 23: 2023-2028 [PMID: 28373768 DOI: 10.3748/wjg.v23.i11.2023]

Wang Y, Abu-Shehi H, Mao E, Ai L, Qiao W, Trinh VA, Zobniw C, Johnson DH, Samdani R, Lum P, Shuttlesworth G, Blechacz B, Bresalier R, Miller E, Thirumurthi S, Richards D, Raju G, Stroehlein J, Diab A. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflamm Bowel Dis 2018; 24: 1695-1705 [PMID: 29713808 DOI: 10.1093/ibd/izy1705]

Coutzac C, Adam J, Soulauer E, Collins M, Racine M, Mussati C, Bessède L, Kamsukon N, Mateus C, Charrier M, Cassard L, Planchar D, Ribrag V, Fizazi K, Loriot Y, Lapgez S, Scoazec JY, Robert C, Carbonnel F, Chaptu N. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entilies. J Crohns Colitis 2017; 11: 1238-1246 [PMID: 28967957 DOI: 10.1093/eco-jcc/jpx081]

Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003; 18: 756-762 [PMID: 12795745 DOI: 10.1046/j.1440-1746.2003.03014.x]

Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith T, Targan SR, Wang HL. Blockade of cytotoxic T-lymphocyte antigen-4 by iplimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10: 11 [PMID: 2109563]

Callahan MK, Yang A, Tandon S, Xu Y, Subudhi SK, Roman RA. Evaluation of serum IL-17 levels during iplimumab therapy: correlation with colitis. J Clin Oncol 2011; 29: 2505 [DOI: 10.1200/jco.2011.32.15_suppl.2505]

Schindler K, Harmankaya K, Kuk D, Mangana J, Michelin O, Hoeller C, Durner U, Pehambemer H, Wolchek JD, Postow A. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with iplimumab. J Clin Oncol 2014; 32: 9906-9909 [PMID: 10.1200/jco.2014.32.15_suppl.9096]

Bergqvist V, Hertberg G, Gedeon P, Kopklar M, Grifsh H, Kinhult S, Carneiro A, Marsal J, Vedolizumab induced colitis and its management with infliximab. Scand J Gastroenterol 2016; 51: 836-842 [PMID: 26748223 DOI: 10.1016/j.cgh.2015.12.028]

Bodizs R, van der Heide H. Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med 2016; 4: 272 [PMID: 27563659 DOI: 10.21037/atm.2016.07.10]

Weber JS, Köhler KC, Hauschild A. Management of immune-related adverse events in melanoma patients treated with ipilimumab. J Clin Oncol 2012; 30: 2691-2697 [PMID: 22641989 DOI: 10.1200/jco.2012.41.6750]

Food and Drug Administration. Highlights of prescribing information. 2011; 1–20 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s000lbl.pdf

Schröder KW, Trennane WJ, Illstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-1629 [PMID: 3317057 DOI: 10.1056/NEJM1987122431722603]

van der Heide H, van den Brandt-Gradel V, Tytgat GN, Endert E, Wiltink EH, Schipper ME, Dekker W. Comparison of beclomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis. J Clin Gastroenterol 1988; 10: 169-172 [PMID: 3047215 DOI: 10.1097/00004836-198904000-00013]

Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009; 54: 2538-2540 [PMID: 19104936 DOI: 10.1007/s10620-008-0641-x]

Brahmer JR, Laccetti C, Schneider BJ, Atkins MB, Brassil KJ, Cervano JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeier SJ, Holzer Chakrabarty J, Leighton CA, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714-1768 [PMID: 29442540 DOI: 10.1200/JCO.2017.77.6385]

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vauthel JM, Linette GP, Hogg D, Ottensooser CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nicholson GM, Hoos A, Urban J. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723 [PMID: 20525992 DOI: 10.1056/NEJMoa1003460]
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalciou C, Chiarión-Silén V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med* 2015; 372: 320-330 [PMID: 25399552 DOI: 10.1056/NEJMoa1412082]

Rastogi P, Sultan M, Charabaty AJ, Atkins MB, Mattar MC. Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital. *World J Gastroenterol* 2015; 21: 4373-4378 [PMID: 2592689 DOI: 10.3748/wjg.v21.i14.4373]

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholf W, Lundhe A, Sandborn WJ. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ Registry. *Am J Gastroenterol* 2014; 109: 212-223 [PMID: 24394749 DOI: 10.1038/ajg.2013.441]

Cohn HM, Dave M, Loftus EV. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2017; 23: 1301-1315 [PMID: 28705006 DOI: 10.1097/MIB.0000000000001189]

Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, Ananthakrishnan AN. Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. *Gastroenterology* 2016; 151: 97-109.e4 [PMID: 27039969 DOI: 10.1053/j.gastro.2016.03.037]

Diana P,Manaungpaisanrung C, Atkins MB, Zeck JC, Charabaty A. Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis. *ACG Case Rep J* 2018; 5: e17 [PMID: 29516018 DOI: 10.14309/crj.2018.17]

Hsieh AH, Ferman M, Brown MP, Andrews JM. Vedolizumab: a novel treatment for ipilimumab-induced colitis. *BMJ Case Rep* 2016; pii: bcr2016216641 [PMID: 27539137 DOI: 10.1136/bcr-2016-216641]

Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Riddolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O’Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. *Clin Cancer Res* 2009; 15: 5591-5598 [PMID: 19671877 DOI: 10.1158/1078-0432.CCR-09-1024]

Smith FO, Goff SL, Klapper JA, Levy C, Allen T, Mavroukakis SA, Rosenberg SA. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. *J Immunother* 2007; 30: 130 [PMID: 17198092 DOI: 10.1097/01.jti.0000211334.06762.89]

P- Reviewer: de Souza HSP, Hughes PAA, Martin-Villa JM
S- Editor: Ji FF
E- Editor: Tan WW
